25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CUV (Clinuvel) Stock Analysis
Buy, Hold or Sell?

Let's analyze Clinuvel together

I guess you are interested in Clinuvel Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Clinuvel’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Clinuvel’s Price Targets

I'm going to help you getting a better view of Clinuvel Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Clinuvel Pharmaceuticals Ltd

I send you an email if I find something interesting about Clinuvel Pharmaceuticals Ltd.

1. Quick Overview

1.1. Quick analysis of Clinuvel (30 sec.)










1.2. What can you expect buying and holding a share of Clinuvel? (30 sec.)

How much money do you get?

How much money do you get?
A$0.13
When do you have the money?
1 year
How often do you get paid?
80.0%

What is your share worth?

Current worth
A$3.98
Expected worth in 1 year
A$7.18
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
A$3.40
Return On Investment
33.5%

For what price can you sell your share?

Current Price per Share
A$10.16
Expected price per share
A$9.41 - A$12.18
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Clinuvel (5 min.)




Live pricePrice per Share (EOD)
A$10.16
Intrinsic Value Per Share
A$4.30 - A$9.73
Total Value Per Share
A$8.28 - A$13.71

2.2. Growth of Clinuvel (5 min.)




Is Clinuvel growing?

Current yearPrevious yearGrowGrow %
How rich?$133m$107.9m$25.1m18.9%

How much money is Clinuvel making?

Current yearPrevious yearGrowGrow %
Making money$23.3m$20m$3.2m14.1%
Net Profit Margin40.4%39.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Clinuvel (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#303 / 881

Most Revenue
#132 / 881

Most Profit
#60 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Clinuvel?

Welcome investor! Clinuvel's management wants to use your money to grow the business. In return you get a share of Clinuvel.

First you should know what it really means to hold a share of Clinuvel. And how you can make/lose money.

Speculation

The Price per Share of Clinuvel is A$10.16. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Clinuvel.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Clinuvel, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$3.98. Based on the TTM, the Book Value Change Per Share is A$0.80 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.75 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.05 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Clinuvel.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.464.5%0.464.5%0.393.8%0.373.6%0.333.2%0.201.9%
Usd Book Value Change Per Share0.535.2%0.535.2%0.494.9%0.454.4%0.373.7%0.242.4%
Usd Dividend Per Share0.030.3%0.030.3%0.030.2%0.020.2%0.020.2%0.010.1%
Usd Total Gains Per Share0.565.5%0.565.5%0.525.1%0.474.6%0.393.9%0.252.5%
Usd Price Per Share10.08-10.08-11.72-10.51-13.69-10.70-
Price to Earnings Ratio22.01-22.01-30.27-29.70-46.07-33.08-
Price-to-Total Gains Ratio18.09-18.09-22.62-23.13-41.99-37.69-
Price to Book Ratio3.86-3.86-5.63-5.20-9.89-13.16-
Price-to-Total Gains Ratio18.09-18.09-22.62-23.13-41.99-37.69-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.65988
Number of shares150
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.030.02
Usd Book Value Change Per Share0.530.37
Usd Total Gains Per Share0.560.39
Gains per Quarter (150 shares)83.5558.93
Gains per Year (150 shares)334.19235.71
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11931532412223226
23863065825446462
35794599237670698
4761261132650893934
595157616606211161170
6114189119947513391406
7133220623288715631642
81522521266210017861878
91712836299611220092114
101903152333012522322350

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.02.00.080.0%8.016.01.032.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%15.010.00.060.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%8.00.02.080.0%8.00.017.032.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%15.010.00.060.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Clinuvel Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.8010.8010%0.752+7%0.682+17%0.568+41%0.367+118%
Book Value Per Share--3.9793.9790%3.177+25%3.194+25%2.588+54%1.595+149%
Current Ratio--8.8088.8080%7.438+18%8.8280%9.478-7%9.525-8%
Debt To Asset Ratio--0.1220.1220%0.154-21%0.136-11%0.123-1%0.118+3%
Debt To Equity Ratio--0.1380.1380%0.182-24%0.158-12%0.141-2%0.135+2%
Dividend Per Share--0.0480.0480%0.038+27%0.037+32%0.032+52%0.022+124%
Enterprise Value--940036866.810940036866.8100%1053389916.360-11%954853763.523-2%1171737762.774-20%892953730.287+5%
Eps--0.6980.6980%0.591+18%0.564+24%0.501+39%0.300+132%
Ev To Ebitda Ratio--18.12518.1250%22.718-20%21.892-17%48.048-62%36.169-50%
Ev To Sales Ratio--10.66110.6610%13.450-21%12.455-14%22.621-53%29.289-64%
Free Cash Flow Per Share--0.6170.6170%0.693-11%0.690-11%0.539+14%0.329+87%
Free Cash Flow To Equity Per Share--0.5470.5470%0.649-16%0.643-15%0.499+10%0.322+70%
Gross Profit Margin--0.3470.3470%0.768-55%0.527-34%0.638-46%0.824-58%
Intrinsic Value_10Y_max--9.728----------
Intrinsic Value_10Y_min--4.300----------
Intrinsic Value_1Y_max--0.753----------
Intrinsic Value_1Y_min--0.359----------
Intrinsic Value_3Y_max--2.432----------
Intrinsic Value_3Y_min--1.146----------
Intrinsic Value_5Y_max--4.315----------
Intrinsic Value_5Y_min--2.004----------
Market Cap509255776.000-54%784280578.810784280578.8100%926470026.360-15%826543599.523-5%1068725199.374-27%829239738.487-5%
Net Profit Margin--0.4040.4040%0.391+3%0.371+9%0.428-6%0.008+5035%
Operating Margin--0.5750.5750%0.582-1%0.560+3%0.514+12%0.023+2451%
Operating Ratio--0.4430.4430%0.478-7%0.472-6%0.509-13%0.981-55%
Pb Ratio2.554-51%3.8633.8630%5.628-31%5.205-26%9.894-61%13.159-71%
Pe Ratio14.548-51%22.00822.0080%30.272-27%29.702-26%46.067-52%33.084-33%
Price Per Share10.160-51%15.37015.3700%17.880-14%16.033-4%20.890-26%16.328-6%
Price To Free Cash Flow Ratio16.470-51%24.91524.9150%25.818-3%23.410+6%50.564-51%35.510-30%
Price To Total Gains Ratio11.957-51%18.08818.0880%22.623-20%23.130-22%41.987-57%37.686-52%
Quick Ratio--14.23014.2300%12.237+16%14.449-2%14.755-4%13.244+7%
Return On Assets--0.1540.1540%0.157-2%0.152+2%0.178-13%0.082+88%
Return On Equity--0.1760.1760%0.186-6%0.1760%0.202-13%0.084+108%
Total Gains Per Share--0.8500.8500%0.790+8%0.719+18%0.599+42%0.389+119%
Usd Book Value--133073950.413133073950.4130%107915714.237+23%107764539.112+23%87051159.462+53%53428852.559+149%
Usd Book Value Change Per Share--0.5250.5250%0.493+7%0.447+17%0.372+41%0.241+118%
Usd Book Value Per Share--2.6082.6080%2.083+25%2.093+25%1.696+54%1.046+149%
Usd Dividend Per Share--0.0320.0320%0.025+27%0.024+32%0.021+52%0.014+124%
Usd Enterprise Value--616194166.194616194166.1940%690497090.174-11%625906641.990-2%768074103.498-20%585331170.203+5%
Usd Eps--0.4580.4580%0.387+18%0.370+24%0.329+39%0.197+132%
Usd Free Cash Flow--20633610.71920633610.7190%23522310.071-12%23335809.177-12%18158309.652+14%11044951.147+87%
Usd Free Cash Flow Per Share--0.4040.4040%0.454-11%0.453-11%0.353+14%0.216+87%
Usd Free Cash Flow To Equity Per Share--0.3580.3580%0.426-16%0.421-15%0.327+10%0.211+70%
Usd Market Cap333817161.168-54%514095919.410514095919.4100%607301102.279-15%541799329.488-5%700549368.190-27%543566648.578-5%
Usd Price Per Share6.660-51%10.07510.0750%11.720-14%10.510-4%13.693-26%10.703-6%
Usd Profit--23359633.32523359633.3250%20061293.013+16%19035586.715+23%16845628.426+39%10062871.214+132%
Usd Revenue--57800880.89457800880.8940%51339623.949+13%50740488.865+14%41003219.205+41%25970913.409+123%
Usd Total Gains Per Share--0.5570.5570%0.518+8%0.471+18%0.393+42%0.255+119%
 EOD+4 -4MRQTTM+0 -0YOY+23 -173Y+22 -185Y+26 -1410Y+30 -10

3.3 Fundamental Score

Let's check the fundamental score of Clinuvel Pharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1514.548
Price to Book Ratio (EOD)Between0-12.554
Net Profit Margin (MRQ)Greater than00.404
Operating Margin (MRQ)Greater than00.575
Quick Ratio (MRQ)Greater than114.230
Current Ratio (MRQ)Greater than18.808
Debt to Asset Ratio (MRQ)Less than10.122
Debt to Equity Ratio (MRQ)Less than10.138
Return on Equity (MRQ)Greater than0.150.176
Return on Assets (MRQ)Greater than0.050.154
Total9/10 (90.0%)

3.4 Technical Score

Let's check the technical score of Clinuvel Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.756
Ma 20Greater thanMa 5010.047
Ma 50Greater thanMa 10010.550
Ma 100Greater thanMa 20010.951
OpenGreater thanClose10.350
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Clinuvel Pharmaceuticals Ltd

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Fundamental data was last updated by Penke on 2025-06-17 23:50:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Clinuvel earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 40.4%Β means thatΒ $0.40 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 40.4%. The company is making a huge profit. +2
  • The TTM is 40.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ40.4%TTM40.4%0.0%
TTM40.4%YOY39.1%+1.3%
TTM40.4%5Y42.8%-2.4%
5Y42.8%10Y0.8%+42.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ40.4%-91.7%+132.1%
TTM40.4%-139.0%+179.4%
YOY39.1%-194.4%+233.5%
3Y37.1%-248.5%+285.6%
5Y42.8%-343.3%+386.1%
10Y0.8%-488.9%+489.7%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Clinuvel is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • 15.4% Return on Assets means thatΒ Clinuvel generatedΒ $0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 15.4%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 15.4%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ15.4%TTM15.4%0.0%
TTM15.4%YOY15.7%-0.3%
TTM15.4%5Y17.8%-2.3%
5Y17.8%10Y8.2%+9.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.4%-11.6%+27.0%
TTM15.4%-11.7%+27.1%
YOY15.7%-11.4%+27.1%
3Y15.2%-11.9%+27.1%
5Y17.8%-12.0%+29.8%
10Y8.2%-13.8%+22.0%
4.3.1.3. Return on Equity

Shows how efficient Clinuvel is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • 17.6% Return on Equity means Clinuvel generated $0.18Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 17.6%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 17.6%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ17.6%TTM17.6%0.0%
TTM17.6%YOY18.6%-1.0%
TTM17.6%5Y20.2%-2.6%
5Y20.2%10Y8.4%+11.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.6%-13.5%+31.1%
TTM17.6%-15.0%+32.6%
YOY18.6%-14.5%+33.1%
3Y17.6%-16.9%+34.5%
5Y20.2%-17.7%+37.9%
10Y8.4%-19.9%+28.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Clinuvel Pharmaceuticals Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Clinuvel is operatingΒ .

  • Measures how much profit Clinuvel makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • An Operating Margin of 57.5%Β means the company generated $0.58 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 57.5%. The company is operating very efficient. +2
  • The TTM is 57.5%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ57.5%TTM57.5%0.0%
TTM57.5%YOY58.2%-0.7%
TTM57.5%5Y51.4%+6.1%
5Y51.4%10Y2.3%+49.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ57.5%-232.5%+290.0%
TTM57.5%-250.3%+307.8%
YOY58.2%-208.4%+266.6%
3Y56.0%-221.7%+277.7%
5Y51.4%-344.1%+395.5%
10Y2.3%-470.4%+472.7%
4.3.2.2. Operating Ratio

Measures how efficient Clinuvel is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.44 means that the operating costs are $0.44 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 0.443. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.443. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.443TTM0.4430.000
TTM0.443YOY0.478-0.035
TTM0.4435Y0.509-0.067
5Y0.50910Y0.981-0.472
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4432.108-1.665
TTM0.4432.680-2.237
YOY0.4783.080-2.602
3Y0.4723.621-3.149
5Y0.5094.734-4.225
10Y0.9816.546-5.565
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Clinuvel Pharmaceuticals Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Clinuvel is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 8.81Β means the company has $8.81 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 8.808. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.808. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.808TTM8.8080.000
TTM8.808YOY7.438+1.370
TTM8.8085Y9.478-0.670
5Y9.47810Y9.525-0.046
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.8083.616+5.192
TTM8.8083.826+4.982
YOY7.4384.141+3.297
3Y8.8284.661+4.167
5Y9.4785.756+3.722
10Y9.5256.149+3.376
4.4.3.2. Quick Ratio

Measures if Clinuvel is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A Quick Ratio of 14.23Β means the company can pay off $14.23 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 14.230. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 14.230. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ14.230TTM14.2300.000
TTM14.230YOY12.237+1.993
TTM14.2305Y14.755-0.525
5Y14.75510Y13.244+1.511
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.2302.799+11.431
TTM14.2303.143+11.087
YOY12.2373.794+8.443
3Y14.4494.307+10.142
5Y14.7555.707+9.048
10Y13.2446.457+6.787
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Clinuvel Pharmaceuticals Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of ClinuvelΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Clinuvel to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12Β means that Clinuvel assets areΒ financed with 12.2% credit (debt) and the remaining percentage (100% - 12.2%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 0.122. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.122. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.122TTM0.1220.000
TTM0.122YOY0.154-0.032
TTM0.1225Y0.123-0.001
5Y0.12310Y0.118+0.005
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1220.327-0.205
TTM0.1220.348-0.226
YOY0.1540.327-0.173
3Y0.1360.340-0.204
5Y0.1230.349-0.226
10Y0.1180.379-0.261
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Clinuvel is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 13.8% means that company has $0.14 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 0.138. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.138. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.138TTM0.1380.000
TTM0.138YOY0.182-0.043
TTM0.1385Y0.141-0.002
5Y0.14110Y0.135+0.005
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1380.379-0.241
TTM0.1380.435-0.297
YOY0.1820.412-0.230
3Y0.1580.448-0.290
5Y0.1410.460-0.319
10Y0.1350.509-0.374
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Clinuvel generates.

  • Above 15 is considered overpriced butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A PE ratio of 22.01 means the investor is paying $22.01Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The EOD is 14.548. Based on the earnings, the company is underpriced. +1
  • The MRQ is 22.008. Based on the earnings, the company is fair priced.
  • The TTM is 22.008. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD14.548MRQ22.008-7.460
MRQ22.008TTM22.0080.000
TTM22.008YOY30.272-8.264
TTM22.0085Y46.067-24.059
5Y46.06710Y33.084+12.983
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD14.548-2.303+16.851
MRQ22.008-2.062+24.070
TTM22.008-2.541+24.549
YOY30.272-3.741+34.013
3Y29.702-3.754+33.456
5Y46.067-6.136+52.203
10Y33.084-6.686+39.770
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The EOD is 16.470. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 24.915. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 24.915. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD16.470MRQ24.915-8.446
MRQ24.915TTM24.9150.000
TTM24.915YOY25.818-0.903
TTM24.9155Y50.564-25.649
5Y50.56410Y35.510+15.055
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD16.470-3.178+19.648
MRQ24.915-2.700+27.615
TTM24.915-3.619+28.534
YOY25.818-4.357+30.175
3Y23.410-5.065+28.475
5Y50.564-8.478+59.042
10Y35.510-9.275+44.785
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Clinuvel is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 3.86 means the investor is paying $3.86Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The EOD is 2.554. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.863. Based on the equity, the company is fair priced.
  • The TTM is 3.863. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.554MRQ3.863-1.310
MRQ3.863TTM3.8630.000
TTM3.863YOY5.628-1.764
TTM3.8635Y9.894-6.031
5Y9.89410Y13.159-3.265
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.5541.963+0.591
MRQ3.8631.848+2.015
TTM3.8632.119+1.744
YOY5.6282.469+3.159
3Y5.2052.526+2.679
5Y9.8943.664+6.230
10Y13.1594.351+8.808
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Clinuvel Pharmaceuticals Ltd.

4.8.2. Funds holding Clinuvel Pharmaceuticals Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2020-10-31Vanguard International Stock Index-Total Intl Stock Indx1.3099999-647827--
2020-12-31Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund0.5-246587--
2021-02-28iShares Core MSCI EAFE ETF0.37-182269--
2021-02-28iShares MSCI EAFE Small Cap ETF0.36000002-177672--
2020-12-31College Retirement Equities Fund-Stock Account0.23-112159--
2021-01-31DFA Asia Pacific Small Company Series0.22-108279--
2020-10-31Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index0.19-95629--
2020-12-31Bernstein Fund, Inc.-International Small Cap Portfolio0.18000001-87490--
2020-11-30Schwab Strategic Tr-Schwab International Small Cap Equity ETF0.11-53643--
2021-01-31DFA International Core Equity Portfolio0.090000004-42853--
Total 3.5599999340175440800.0%
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-06-302021-06-302022-06-302023-06-302024-06-30
Retained Earnings  -81,63323,503-58,13019,727-38,40228,628-9,77439,73829,964
Long-term Assets Other  -2,574-214-2,788-97-2,885-151-3,0364,0571,020



5.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets231,124
Total Liabilities28,112
Total Stockholder Equity203,011
 As reported
Total Liabilities 28,112
Total Stockholder Equity+ 203,011
Total Assets = 231,124

Assets

Total Assets231,124
Total Current Assets222,064
Long-term Assets9,060
Total Current Assets
Cash And Cash Equivalents 183,868
Short-term Investments 148,668
Net Receivables 26,238
Other Current Assets 1,330
Total Current Assets  (as reported)222,064
Total Current Assets  (calculated)360,105
+/- 138,041
Long-term Assets
Property Plant Equipment 7,720
Long Term Investments 134
Intangible Assets 185
Long-term Assets Other 1,020
Long-term Assets  (as reported)9,060
Long-term Assets  (calculated)9,060
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities25,212
Long-term Liabilities2,900
Total Stockholder Equity203,011
Total Current Liabilities
Short-term Debt 370
Accounts payable 2,345
Other Current Liabilities 6,646
Total Current Liabilities  (as reported)25,212
Total Current Liabilities  (calculated)9,361
+/- 15,851
Long-term Liabilities
Capital Lease Obligations 880
Long-term Liabilities  (as reported)2,900
Long-term Liabilities  (calculated)880
+/- 2,020
Total Stockholder Equity
Common Stock168,802
Retained Earnings 29,964
Accumulated Other Comprehensive Income 4,245
Total Stockholder Equity (as reported)203,011
Total Stockholder Equity (calculated)203,011
+/-0
Other
Capital Stock168,802
Cash and Short Term Investments 183,868
Common Stock Shares Outstanding 51,027
Liabilities and Stockholders Equity 231,124
Net Debt -182,989
Net Invested Capital 203,011
Net Working Capital 196,852
Property Plant and Equipment Gross 10,660
Short Long Term Debt Total 880



5.3. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-30
> Total Assets 
15,441
13,769
10,520
8,066
10,247
10,056
17,071
67,825
54,971
41,614
29,507
20,165
15,995
15,815
17,154
13,644
20,138
28,607
42,905
62,345
81,542
108,568
144,814
194,525
231,124
231,124194,525144,814108,56881,54262,34542,90528,60720,13813,64417,15415,81515,99520,16529,50741,61454,97167,82517,07110,05610,2478,06610,52013,76915,441
   > Total Current Assets 
7,995
7,028
4,483
2,748
5,682
5,246
13,917
65,317
53,120
40,594
29,158
19,932
15,807
15,668
17,039
13,575
19,974
28,470
42,269
61,153
75,156
102,848
140,583
189,618
222,064
222,064189,618140,583102,84875,15661,15342,26928,47019,97413,57517,03915,66815,80719,93229,15840,59453,12065,31713,9175,2465,6822,7484,4837,0287,995
       Cash And Cash Equivalents 
7,927
6,981
4,414
2,612
5,480
4,763
8,606
33,842
25,752
21,711
19,415
12,178
12,719
12,569
14,626
10,572
13,845
23,752
36,198
54,269
25,652
37,141
27,409
23,867
183,868
183,86823,86727,40937,14125,65254,26936,19823,75213,84510,57214,62612,56912,71912,17819,41521,71125,75233,8428,6064,7635,4802,6124,4146,9817,927
       Short-term Investments 
0
0
0
0
0
0
2,024
28,512
25,048
16,043
7,588
5,321
454
0
0
0
0
9,542
19,569
28,525
41,095
45,550
94,100
132,946
148,668
148,668132,94694,10045,55041,09528,52519,5699,54200004545,3217,58816,04325,04828,5122,024000000
       Net Receivables 
57
35
30
31
78
137
233
53
157
11
118
866
952
1,697
1,059
1,478
2,759
2,966
4,937
3,759
6,613
16,089
16,202
22,215
26,238
26,23822,21516,20216,0896,6133,7594,9372,9662,7591,4781,0591,69795286611811157532331377831303557
       Other Current Assets 
10
13
39
106
124
314
2,474
2,722
1,703
2,628
1,791
1,460
1,627
1,357
828
687
2,288
510
492
989
509
882
1,039
1,070
1,330
1,3301,0701,0398825099894925102,2886878281,3571,6271,4601,7912,6281,7032,7222,474314124106391310
   > Long-term Assets 
7,446
6,741
6,037
5,318
4,565
4,810
3,154
2,508
1,851
1,020
349
233
188
146
114
69
165
137
354
892
6,386
5,719
4,231
4,907
9,060
9,0604,9074,2315,7196,386892354137165691141461882333491,0201,8512,5083,1544,8104,5655,3186,0376,7417,446
       Property Plant Equipment 
94
116
141
147
120
249
222
332
431
357
322
215
179
146
114
69
165
137
169
707
2,389
2,603
2,700
2,851
7,720
7,7202,8512,7002,6032,3897071691371656911414617921532235743133222224912014714111694
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
185
185
185
185
185
185
0
0185185185185185185000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
134
134000000000000000000000000
       Intangible Assets 
7,352
6,624
5,896
5,171
4,445
4,561
2,932
2,176
1,420
663
28
18
9
0
0
0
0
0
185
185
185
185
185
185
185
18518518518518518518500000918286631,4202,1762,9324,5614,4455,1715,8966,6247,352
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
282
301
3,812
0
482
1,060
0
01,06048203,812301282000000000000000000
> Total Liabilities 
124
318
211
535
1,392
2,601
3,082
2,433
3,156
4,563
3,081
3,757
2,358
1,976
1,726
2,439
2,304
3,163
3,489
5,166
9,475
9,830
19,255
29,894
28,112
28,11229,89419,2559,8309,4755,1663,4893,1632,3042,4391,7261,9762,3583,7573,0814,5633,1562,4333,0822,6011,392535211318124
   > Total Current Liabilities 
124
318
211
535
1,370
2,577
3,067
2,428
3,147
4,544
3,040
3,717
2,339
1,946
1,718
2,435
2,288
3,148
3,471
4,960
8,262
8,707
13,732
25,495
25,212
25,21225,49513,7328,7078,2624,9603,4713,1482,2882,4351,7181,9462,3393,7173,0404,5443,1472,4283,0672,5771,370535211318124
       Short-term Debt 
0
0
0
0
0
0
2,024
28,512
25,048
16,043
7,588
5,321
454
0
0
0
0
0
0
261
212
258
-6,964
-15,793
370
370-15,793-6,9642582122610000004545,3217,58816,04325,04828,5122,024000000
       Accounts payable 
115
183
69
236
1,180
2,346
2,535
1,597
734
2,056
569
1,697
839
184
178
261
231
579
429
1,500
1,430
2,324
259
2,792
2,345
2,3452,7922592,3241,4301,5004295792312611781848391,6975692,0567341,5972,5352,3461,18023669183115
       Other Current Liabilities 
9
135
141
300
191
231
532
831
2,413
2,488
2,471
2,020
1,500
1,762
1,540
2,175
2,057
2,568
3,042
3,460
6,620
6,125
-1,401
-9,786
6,646
6,646-9,786-1,4016,1256,6203,4603,0422,5682,0572,1751,5401,7621,5002,0202,4712,4882,4138315322311913001411359
   > Long-term Liabilities 
0
0
0
0
22
24
15
5
9
19
41
40
19
29
8
3
15
15
18
205
1,213
1,123
5,523
4,399
2,900
2,9004,3995,5231,1231,213205181515382919404119951524220000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
171
1,107
1,045
941
699
0
06999411,0451,1071710000000000000000000
       Other Liabilities 
0
0
0
0
22
24
15
5
9
19
41
40
19
29
8
3
15
15
18
34
106
78
3,717
2,889
0
02,8893,7177810634181515382919404119951524220000
> Total Stockholder Equity
15,317
13,451
10,310
7,531
8,855
7,454
13,989
65,392
51,815
37,051
26,426
16,408
13,637
13,839
15,428
11,222
17,796
25,386
39,416
57,180
72,067
98,737
125,559
164,631
203,011
203,011164,631125,55998,73772,06757,18039,41625,38617,79611,22215,42813,83913,63716,40826,42637,05151,81565,39213,9897,4548,8557,53110,31013,45115,317
   Common Stock
15,692
15,382
15,382
16,580
25,494
35,123
52,726
112,813
113,222
113,221
113,228
113,339
119,323
126,710
133,567
138,465
146,765
148,413
148,615
151,314
151,849
151,849
151,849
151,849
168,802
168,802151,849151,849151,849151,849151,314148,615148,413146,765138,465133,567126,710119,323113,339113,228113,221113,222112,81352,72635,12325,49416,58015,38215,38215,692
   Retained Earnings 
-374
-1,932
-5,073
-9,050
-16,639
-27,668
-39,890
-49,066
-63,172
-78,337
-88,971
-100,145
-107,507
-114,122
-119,577
-129,942
-133,063
-125,847
-112,681
-95,487
-81,633
-58,130
-38,402
-9,774
29,964
29,964-9,774-38,402-58,130-81,633-95,487-112,681-125,847-133,063-129,942-119,577-114,122-107,507-100,145-88,971-78,337-63,172-49,066-39,890-27,668-16,639-9,050-5,073-1,932-374
   Accumulated Other Comprehensive Income 
-5
-41
-80
-123
-152
-164
1,153
1,645
1,764
2,167
2,169
3,214
1,821
1,251
1,438
2,698
4,095
2,820
3,482
1,352
1,850
5,018
12,112
22,556
4,245
4,24522,55612,1125,0181,8501,3523,4822,8204,0952,6981,4381,2511,8213,2142,1692,1671,7641,6451,153-164-152-123-80-41-5
   Capital Surplus 0000000000000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
5
41
80
123
0
0
0
0
0
0
0
0
0
0
1,438
385
111
2,820
3,482
1,352
0
-93,720
-113,447
-142,075
0
0-142,075-113,447-93,72001,3523,4822,8201113851,438000000000012380415



5.4. Balance Sheets

Currency in AUD. All numbers in thousands.




5.5. Cash Flows

Currency in AUD. All numbers in thousands.




5.6. Income Statements

Currency in AUD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue88,178
Cost of Revenue-7,733
Gross Profit80,44580,445
 
Operating Income (+$)
Gross Profit80,445
Operating Expense-31,297
Operating Income48,00649,148
 
Operating Expense (+$)
Research Development2,348
Selling General Administrative1,743
Selling And Marketing Expenses23,282
Operating Expense31,29727,373
 
Net Interest Income (+$)
Interest Income7,325
Interest Expense-4,454
Other Finance Cost-0
Net Interest Income2,871
 
Pretax Income (+$)
Operating Income48,006
Net Interest Income2,871
Other Non-Operating Income Expenses0
Income Before Tax (EBT)50,67945,333
EBIT - interestExpense = 46,266
50,679
40,091
Interest Expense4,454
Earnings Before Interest and Taxes (EBIT)50,72155,133
Earnings Before Interest and Taxes (EBITDA)51,863
 
After tax Income (+$)
Income Before Tax50,679
Tax Provision-15,043
Net Income From Continuing Ops35,63635,636
Net Income35,636
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses39,030
Total Other Income/Expenses Net2,673-2,871
 

Technical Analysis of Clinuvel
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Clinuvel. The general trend of Clinuvel is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Clinuvel's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Clinuvel Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Clinuvel Pharmaceuticals Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 11.25 < 11.79 < 12.18.

The bearish price targets are: 9.41.

Know someone who trades $CUV? Share this with them.πŸ‘‡

Clinuvel Pharmaceuticals Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Clinuvel Pharmaceuticals Ltd. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Clinuvel Pharmaceuticals Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Clinuvel Pharmaceuticals Ltd. The current macd is -0.08053745.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Clinuvel price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Clinuvel. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Clinuvel price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Clinuvel Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) ChartClinuvel Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Clinuvel Pharmaceuticals Ltd. The current adx is 16.88.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Clinuvel shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Clinuvel Pharmaceuticals Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Clinuvel Pharmaceuticals Ltd. The current sar is 9.78447229.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Clinuvel Pharmaceuticals Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Clinuvel Pharmaceuticals Ltd. The current rsi is 48.76. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Clinuvel Pharmaceuticals Ltd Daily Relative Strength Index (RSI) ChartClinuvel Pharmaceuticals Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Clinuvel Pharmaceuticals Ltd. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Clinuvel price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Clinuvel Pharmaceuticals Ltd Daily Stochastic Oscillator ChartClinuvel Pharmaceuticals Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Clinuvel Pharmaceuticals Ltd. The current cci is 44.97.

Clinuvel Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) ChartClinuvel Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Clinuvel Pharmaceuticals Ltd. The current cmo is 1.21449708.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Clinuvel Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) ChartClinuvel Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Clinuvel Pharmaceuticals Ltd. The current willr is -45.65217391.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Clinuvel is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Clinuvel Pharmaceuticals Ltd Daily Williams %R ChartClinuvel Pharmaceuticals Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Clinuvel Pharmaceuticals Ltd. The current atr is 0.41642638.

Clinuvel Pharmaceuticals Ltd Daily Average True Range (ATR) ChartClinuvel Pharmaceuticals Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Clinuvel Pharmaceuticals Ltd. The current obv is -6,159,469.

Clinuvel Pharmaceuticals Ltd Daily On-Balance Volume (OBV) ChartClinuvel Pharmaceuticals Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Clinuvel Pharmaceuticals Ltd. The current mfi is 72.43.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Clinuvel Pharmaceuticals Ltd Daily Money Flow Index (MFI) ChartClinuvel Pharmaceuticals Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Clinuvel Pharmaceuticals Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-03BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-03BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-07-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-04STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Clinuvel Pharmaceuticals Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Clinuvel Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.756
Ma 20Greater thanMa 5010.047
Ma 50Greater thanMa 10010.550
Ma 100Greater thanMa 20010.951
OpenGreater thanClose10.350
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Clinuvel with someone you think should read this too:
  • Are you bullish or bearish on Clinuvel? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Clinuvel? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Clinuvel Pharmaceuticals Ltd

I send you an email if I find something interesting about Clinuvel Pharmaceuticals Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Clinuvel Pharmaceuticals Ltd.

Receive notifications about Clinuvel Pharmaceuticals Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.